Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

Response letter to 'does high LDL-cholesterol cause cardiovascular disease?'

Ravnskov U, De Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

Expert Rev Clin Pharmacol. 2019 Feb;12(2):93-94. doi: 10.1080/17512433.2019.1561102. Epub 2019 Jan 16. No abstract available.

PMID:
30563359
2.

LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature.

Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

Expert Rev Clin Pharmacol. 2018 Oct;11(10):959-970. doi: 10.1080/17512433.2018.1519391. Epub 2018 Oct 11. Review.

PMID:
30198808
3.

Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review.

Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

BMJ Open. 2016 Jun 12;6(6):e010401. doi: 10.1136/bmjopen-2015-010401. Review.

4.

[Prescription practice must be correct also when it comes to diet].

Sundberg R, Scherstén T.

Lakartidningen. 2014 Aug 20-Sep 2;111(34-35):1370-1; discussion 1371-2. Swedish. No abstract available.

5.

[A statin pill too much].

Ravnskov U, Arfors KE, Enkvist C, Scherstén T, Sundberg R, Nielsen JV.

Lakartidningen. 2011 Oct 26-Nov 1;108(43):2169-70; discussion 2170-1. Swedish. No abstract available.

PMID:
22167980
6.

The cholesterol hypothesis: time for the obituary?

Scherstén T, Rosch PJ, Arfors KE, Sundberg R.

Scand Cardiovasc J. 2011 Dec;45(6):322-3. doi: 10.3109/14017431.2011.613203.

PMID:
22070401
7.

Medical publication under fire.

Scherstén T.

Scand Cardiovasc J. 2010 Dec;44(6):319-20. doi: 10.3109/14017431.2010.525881. No abstract available.

PMID:
21080862
8.

[The cholesterol myth kept alive by artificial breathing].

Sundberg R, Scherstén T.

Lakartidningen. 2010 Jun 16-29;107(24-25):1637-8; discussion 1639. Swedish. No abstract available.

PMID:
20687428
9.

Introductory remarks. Dietary fats and cholesterol--facts and myths.

Schersten T.

Scand Cardiovasc J. 2008 Aug;42(4):235. doi: 10.1080/14017430802319260. No abstract available.

PMID:
18668400
10.
11.

Health technology assessment in policy and practice. Working group 6 report.

von Below GC, Boer A, Conde-Olasagasti JL, Dillon A, Gibis B, Grilli R, Hardy C, Liaropoulos L, Martín-Moreno JM, Roine R, Scherstén T, Søreide O, Züllig M.

Int J Technol Assess Health Care. 2002 Spring;18(2):447-55. No abstract available.

PMID:
12053429
12.

Health technology assessment and screening in Sweden.

Jonsson E, Banta HD, Schersten T.

Int J Technol Assess Health Care. 2001 Summer;17(3):380-8.

PMID:
11495381
13.

Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.

Lindnér P, Fjälling M, Hafström L, Kierulff-Nielsen H, Mattsson J, Scherstén T, Rizell M, Naredi P.

Eur J Surg Oncol. 1999 Apr;25(2):179-85.

PMID:
10218462
14.

Treatment of primary liver cancer.

Hafström L, Naredi P, Lindnér P, Holmberg S, Scherstén T.

Eur J Surg. 1998 Aug;164(8):569-74.

PMID:
9720932
15.

Indication for isolated hyperthermic liver perfusion: a surgeon's view.

Scherstén T.

Recent Results Cancer Res. 1998;147:13-5.

PMID:
9670264
16.

In vivo 31P NMR OSIRIS of bioenergetic changes in rabbit kidneys during and after ischaemia: effect of pretreatment with an indeno-indole compound.

Sørensen V, Jonsson O, Pettersson S, Scherstén T, Soussi B.

Acta Physiol Scand. 1998 Apr;162(4):495-500.

PMID:
9597117
17.

Effects of pretreatment with an indeno-indole compound on lipid peroxidation in the cortex and medulla of rabbit kidneys after ischaemia-reperfusion.

Sørensen V, Nilsson U, Pettersson S, Scherstén T, Sjöquist PO, Svensson L, Jonsson O.

Acta Physiol Scand. 1997 Nov;161(3):403-9.

PMID:
9401594
18.

Purine nucleotides and phospholipids in ischemic and reperfused rat skeletal muscle: effect of ascorbate.

Lagerwall K, Madhu B, Daneryd P, Scherstén T, Soussi B.

Am J Physiol. 1997 Jan;272(1 Pt 2):H83-90.

PMID:
9038925
19.

Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.

Wängberg B, Westberg G, Tylén U, Tisell L, Jansson S, Nilsson O, Johansson V, Scherstén T, Ahlman H.

World J Surg. 1996 Sep;20(7):892-9; discussion 899.

PMID:
8678968
20.

Effect of a new inhibitor of lipid peroxidation on kidney function after ischaemia-reperfusion. A study on rat and rabbit kidneys.

Sørensen V, Nilsson U, Pettersson S, Scherstén T, Sjöqvist PO, Svensson L, Jonsson O.

Acta Physiol Scand. 1996 Jun;157(2):289-97.

PMID:
8800371
21.

Treatment of liver metastases of carcinoid tumors.

Ahlman H, Westberg G, Wängberg B, Nilsson O, Tylén U, Scherstén T, Tisell LE.

World J Surg. 1996 Feb;20(2):196-202. Review.

PMID:
8661817
22.

Disturbed energy balance in skeletal muscle of patients with untreated primary hypertension.

Ronquist G, Soussi B, Frithz G, Scherstén T, Waldenström A.

J Intern Med. 1995 Aug;238(2):167-74.

PMID:
7629485
23.

Effect of pre-treatment with desferrioxamine and mannitol on radical production and kidney function after ischaemia-reperfusion. A study on rabbit kidneys.

Haraldsson G, Sörensen V, Nilsson U, Pettersson S, Rashid M, Scherstén T, Akerlund S, Jonsson O.

Acta Physiol Scand. 1995 Aug;154(4):461-8.

PMID:
7484172
24.
25.

Coenzymes Q9 and Q10 in skeletal and cardiac muscle in tumour-bearing exercising rats.

Daneryd P, Aberg F, Dallner G, Ernster L, Scherstén T, Soussi B.

Eur J Cancer. 1995;31A(5):760-5.

PMID:
7503906
26.

Purine metabolism during microsurgical transfer of human skeletal muscle.

Elander A, Fogdestam I, Scherstén T, Soussi B.

Scand J Plast Reconstr Surg Hand Surg. 1994 Dec;28(4):261-8.

PMID:
7899835
27.

Effect of pretreatment with a new inhibitor of lipid peroxidation after reperfusion ischemia: a study of rabbit kidneys.

Sørensen V, Nilsson U, Pettersson S, Scherstén T, Jonsson O.

Transplant Proc. 1994 Jun;26(3):1774-5. No abstract available.

PMID:
8030129
28.

Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy.

Hafström LR, Holmberg SB, Naredi PL, Lindnér PG, Bengtsson A, Tidebrant G, Scherstén TS.

Surg Oncol. 1994 Apr;3(2):103-8.

PMID:
7952389
29.

Purine metabolic pathways in rat hindlimb perfusion model during ischemia and reperfusion.

Soussi B, Lagerwall K, Idström JP, Scherstén T.

Am J Physiol. 1993 Oct;265(4 Pt 2):H1074-81.

PMID:
8238394
30.

Phosphocreatine turnover and pH balance in forearm muscle of patients with syndrome X.

Soussi B, Scherstén T, Waldenström A, Ronquist G.

Lancet. 1993 Mar 27;341(8848):829-30. No abstract available.

PMID:
8096030
31.

ESR-measurement of oxygen radicals in vivo after renal ischaemia in the rabbit. Effects of pre-treatment with superoxide dismutase and heparin.

Nilsson UA, Haraldsson G, Bratell S, Sørensen V, Akerlund S, Pettersson S, Scherstén T, Jonsson O.

Acta Physiol Scand. 1993 Mar;147(3):263-70.

PMID:
8386425
32.

Adrenocortical carcinoma--diagnostic and therapeutical implications.

Ahlman H, Jansson S, Wängberg B, Tisell LE, Scherstén T, Hansson G, Bengtsson BA, Ernest I, Jakobsson CE, Lindstedt S.

Eur J Surg. 1993 Mar;159(3):149-58.

PMID:
8102889
33.

[The university hospital--problems and solutions. Avoid centralization of research!].

Scherstén T.

Lakartidningen. 1993 Feb 17;90(7):547-9. Swedish. No abstract available.

PMID:
8437456
34.

The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study.

Sandström R, Drott C, Hyltander A, Arfvidsson B, Scherstén T, Wickström I, Lundholm K.

Ann Surg. 1993 Feb;217(2):185-95.

35.

Implications of minimally invasive therapy.

Banta HD, Schersten T, Jonsson E.

Health Policy. 1993 Jan;23(1-2):167-77.

PMID:
10171341
36.

[The MFR system for project applications: information to the scientists is better. The Australian system is not suitable for Sweden].

Scherstén T.

Lakartidningen. 1992 Dec 9;89(50):4339-40. Swedish. No abstract available.

PMID:
1469960
37.

ESR-measurement of production of oxygen radicals in vivo before and after renal ischaemia in the rabbit.

Haraldsson G, Nilsson U, Bratell S, Pettersson S, Scherstén T, Akerlund S, Jonsson O.

Acta Physiol Scand. 1992 Sep;146(1):99-105.

PMID:
1332422
38.

[Liver transplantation--experiences from the first 100 cases in Gothenburg].

Friman S, Persson H, Henriksson BA, Nordén G, Stenquist O, Wijnveen AC, Scherstén T, Karlberg I.

Lakartidningen. 1992 Jun 10;89(24):2203-6. Swedish. No abstract available.

PMID:
1630252
39.

Aspects on diagnosis and treatment of the foregut carcinoid syndrome.

Ahlman H, Wängberg B, Nilsson O, Grimelius L, Granérus G, Modlin IM, Stenqvist O, Scherstén T.

Scand J Gastroenterol. 1992 Jun;27(6):459-71.

PMID:
1385890
40.

[After an American model: it is time to demand continuous registration of both the processes and the results of Swedish health care].

Scherstén T.

Lakartidningen. 1992 May 6;89(19):1686-9. Swedish. No abstract available.

PMID:
1579037
41.

[Research fraud--an increasing ethical problem].

Scherstén T.

Lakartidningen. 1992 Apr 8;89(15):1307-10. Swedish. No abstract available.

PMID:
1579003
42.

[Laparoscopic cholecystectomy is a revolutionary surgical alternative in gallstones].

Arvidsson D, Haglund U, Scherstén T, Svanvik J.

Lakartidningen. 1992 Feb 5;89(6):395-6. Swedish. No abstract available.

PMID:
1531374
43.

Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.

Friman S, Persson H, Scherstén T, Svanvik J, Karlberg I.

Transplant Proc. 1992 Feb;24(1):389-90. No abstract available.

PMID:
1539328
44.

Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.

Friman S, Persson H, Scherstén T, Svanvik J, Karlberg I.

Transpl Int. 1992;5 Suppl 1:S187-9.

PMID:
14621771
45.

Volume and outcome of organ transplantation.

Banta HD, Engel GL, Scherstén T.

Int J Technol Assess Health Care. 1992 Summer;8(3):490-505. Review.

PMID:
1399333
46.

Cytochrome c oxidase and purine nucleotides in skeletal muscle in tumour-bearing exercising rats.

Daneryd P, Karlberg I, Scherstén T, Soussi B.

Eur J Cancer. 1992;28A(4-5):773-7.

PMID:
1326306
47.

Chronic lower limb ischaemia. A prospective randomised controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA).

Holm J, Arfvidsson B, Jivegård L, Lundgren F, Lundholm K, Scherstén T, Stenberg B, Tylén U, Zachrisson BF, Lindberg H, et al.

Eur J Vasc Surg. 1991 Oct;5(5):517-22.

PMID:
1835704
48.

[Medical prioritization instead of rationing].

Scherstén T, Brorsson B.

Lakartidningen. 1991 Sep 4;88(36):2847-9. Swedish. No abstract available.

PMID:
1895833
49.

Hyperthermic liver perfusion chemotherapy in the foregut carcinoid syndrome.

Scherstén T, Ahlman H, Wängberg B, Granérus G, Grimelius L.

Lancet. 1991 Aug 31;338(8766):568-9. No abstract available.

PMID:
1678816
50.

[Established and experimental methods of treatment of liver cancer].

Hafström L, Adami HO, Glimelius B, Järhult J, Karlberg I, Scherstén T, Stigbrand T.

Lakartidningen. 1991 Apr 17;88(16):1497-501. Swedish. No abstract available.

PMID:
2023501

Supplemental Content

Loading ...
Support Center